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A B S T R A C T
Liver ischaemia-reperfusion injury (IRI) may occur during hepatic surgery and is unavoidable in liver trans-
plantation. Superoxide dismutase enzymosomes (SOD-enzymosomes), liposomes where SOD is at the liposomal
surface expressing enzymatic activity in intact form without the need of liposomal disruption, were developed
with the aim of having a better insight into its antioxidant therapeutic outcome in IRI. We also aimed at vali-
dating magnetic resonance microscopy (MRM) at 7 T as a tool to follow IRI. SOD-enzymosomes were char-
acterized and tested in a rat ischaemia-reperfusion model and the therapeutic outcome was compared with
conventional long circulating SOD liposomes and free SOD using biochemical liver injury biomarkers, histology
and MRM. MRM results correlated with those obtained using classical biochemical biomarkers of liver injury and
liver histology. Moreover, MRM images suggested that the therapeutic eﬃcacy of both SOD liposomal for-
mulations used was related to prevention of peripheral biliary ductular damage and disrupted vascular archi-
tecture. Therefore, MRM at 7 T is a useful technique to follow IRI. SOD-enzymosomes were more eﬀective than
conventional liposomes in reducing liver ischaemia-reperfusion injury and this may be due to a short therapeutic
window.
1. Introduction
The interruption of blood ﬂow to the liver is common during hepatic
surgery and unavoidable in liver transplantation (LT). The lack of blood
supply and consequent lack of oxygen and nutrients leads to cell da-
mage through several mechanisms. This damage can be further ex-
acerbated during liver revascularization (reperfusion), a clinical phe-
nomenon known either as post-reperfusion syndrome or as ischaemia-
reperfusion (IR) injury (IRI).
Liver injury due to ischaemia-reperfusion can be divided into two
major categories. The ﬁrst is warm IRI, which is initiated by hepatocyte
damage and which occurs when the blood ﬂow is temporarily inter-
rupted during transplantation, trauma and shock and elective liver
surgery. The second is cold IRI which is initiated by damage to hepatic
sinusoidal endothelial cells and microcirculation disruption occurs
when organs are preserved for transplantation and is usually coupled
with warm IRI during LT (Klune and Tsung, 2010; Zhai et al., 2013).
The hallmark of IRI is the local inﬂammatory innate immune
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activation response that is triggered. In liver IRI there is initially an
ischemic injury, which includes a series of molecular events occurring
during hypoxia which may lead to cell death after depletion of cellular
ATP. This response is directed at organ preservation and repair, and is
genetically determined, and thus can vary from patient to patient. In
the reperfusion phase of IRI, two distinctive phases can be singled out:
the ﬁrst phase, occurring in the initial 1–2 h of reperfusion, is char-
acterized by a signiﬁcantly impaired microcirculation which prolongs
the period of hypoxia, with areas of the liver remaining ischemic after
the onset of reperfusion (Serracino-Inglott et al., 2001). This in turn is
followed by activation of immunocompetent cells, like resident liver
macrophages (Kupﬀer cells) and generation of reactive oxygen species
(ROS), such as superoxide radical (O2%−) and hydrogen peroxide
(H2O2), and reactive nitrogen (RNS) species, such as nitric oxide (%NO)
and peroxynitrite (ONOO−), leading to an initial stage of the in-
ﬂammatory process and to oxidative stress. Activation of liver Kupﬀer
cells is associated not only with increased rates of formation of ROS and
RNS, but also with the release of proinﬂammatory cytokines (TNF-α, IL-
1β, IFN-γ, and others), chemokines (MIP-2, MCP-1) and adhesion mo-
lecules, which mediate signalling pathways ensuing the recruitment of
inﬂammatory cells, such as neutrophils, and liver inﬁltration by neu-
trophils (Diesen and Kuo, 2011; Jaeschke, 2011; Klune and Tsung,
2010). The second phase, occurring 6–48 h after reperfusion, involves
accumulation of neutrophils and hepatocellular injury (Jaeschke and
Farhood, 2002; Klune and Tsung, 2010; Lutz et al., 2010).
High levels and/or inadequate removal of O2%− and H2O2 by an-
tioxidant enzymes results in molecular damage and disruption of redox
signalling i.e., oxidative stress, which may cause oxidative stress-
mediated diseases. O2%− main reactions in vivo are its dismutation,
catalyzed by superoxide dismutases (SODs), to form H2O2 and oxygen
and its reaction with nitric oxide to form peroxynitrite (Beckman and
Koppenol, 1996). Superoxide dismutases started to be used as anti-
oxidant therapy for inﬂammatory situations in the late 60s. Since then,
SODs therapy has been shown to have a protective role, not just for
inﬂammatory diseases, but also for other pathological situations where
O2%− and endogenous SODs have a key role (Corvo et al., 2016). In
fact, SODs have been used both in animal models and, also clinically,
displaying positive therapeutic outcomes for rheumatoid arthritis,
cancer, ischaemia-reperfusion injury, respiratory diseases, nervous
tissue damage, infectious diseases and also for radiation side eﬀects,
such as ﬁbrosis (Carillon et al., 2013).
Recently we began studies to establish both the therapeutic eﬀec-
tiveness of diﬀerent liposomal formulations of bovine CuZn-SOD on
animal models of arthritis and IRI, as well as to test a new contrast
agent for Magnetic Resonance Imaging (MRI) with high spatial re-
solution (magnetic resonance microscopy, MRM) (Corvo et al., 2015;
Martins et al., 2014). MRM has been suggested as a promising tech-
nique for medical imaging not only to diagnose acute ischaemia but
also to follow up the complex chain of events that follows an acute
ischaemia (Cheung et al., 2011; Martins et al., 2014). MRM can be used
on live animals and when used for imaging of ﬁxed specimens has
advantages over conventional microscopy because it is non-destructive,
can be 3D, and is inherently digital (Driehuys et al., 2008). Moreover,
since the ﬁxed samples do not have to be dehydrated for MRM, as it
happens in conventional histology, MRM images display the natural
distribution of water in tissues and organs and provide a detailed
functional and anatomical picture thus allowing to characterize lesions
not possible to visualize in other conditions (Driehuys et al., 2008). We
developed long circulating liposomes with SOD covalently linked to the
distal end of DSPE-PEG (SOD-enzymosomes) which when tested in an
animal model of arthritis showed an enhanced therapeutic result. An
animal model of liver IRI was used to make a preliminary assessment of
the outcome of treatment with SOD-enzymosomes and with SOD-long
circulating liposomes (SOD-liposomes). We found that treatment with
SOD-enzymosomes, unlike SOD-liposomes or free SOD, decreased sig-
niﬁcantly alanine aminotransferase (AST) activity in serum, a
biomarker of liver cell damage due to IRI. As previously demonstrated,
both these nanosystems have long circulating capabilities and enhanced
retention at inﬂamed sites/pathologies (Corvo et al., 1999, 2015;
Martins et al., 2014). At 24 h post-injection, both formulations have
similar biodistribution proﬁles, namely in the liver (Corvo et al., 2015).
However, SOD-enzymosomes have a unique capability of expressing
enzymatic activity in intact form without the need of liposomal dis-
ruption, thus enabling a faster therapeutic outcome when compared to
SOD-liposomes. Our previous results suggested that a therapeutic ap-
proach to IRI using SOD-enzymosomes would be beneﬁcial, decreasing
liver cell damage due to ischaemia-reperfusion. Here we aimed at fur-
ther characterizing the therapeutic eﬀect of the administration of two
liposomal formulations of SOD (SOD-long circulating liposomes) and
SOD-enzymosomes in the ﬁnal stage of liver ischaemia induced in rats
by evaluating their eﬀect on IRI. We also aimed at validating MRM as a
tool to follow IRI by using known liver injury biochemical biomarkers
and histological analyses.
2. Materials and methods
2.1. Materials
1,2-Distearoyl-sn-glycero-3-phosphoethanolamine-N-[maleimide
(polyethylene glycol)-2000] (ammonium salt), (maleimide-PEG-PE)
was purchased from Avanti Polar Lipids. Egg-phosphatidylcholine (PC)
and 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy
(polyethylene glycol)-2000] (PEG-PE) were obtained from Lipoid
GmbH. Bovine Cu,Zn-superoxide dismutase (SOD), dimethylformamide
(DMF), N-(2-hydroxyethyl) and Cholesterol (Chol), were obtained from
Sigma. Ethylenediaminetetraacetic (EDTA) was from Merck. N-succi-
nimidyl S-acethylthioacetate (SATA) was from Pierce. Imalgene 1000®
(ketamine) was obtained from Merial Portuguesa Saúde Animal Lda,
Rio de Mouro, Portugal and Domitor® (medetomidine) and Antisedam®
(atipamezole) were obtained from Pﬁzer Animal Health, Pennsylvania,
EUA.
2.2. Animals
For the therapeutic activity experiments male Wistar rats weighting
200–250 g were provided by Instituto Bento da Rocha Cabral, Lisbon,
Portugal. Animals were fed with standard laboratory food and water ad
libitum. All animal experiments were carried with the permission of the
local animal ethical committee, and in accordance with the Declaration
of Helsinki, EEC Directive (2010/63/UE) and Portuguese Law (DL 113/
2013, Despacho n° 2880/2015), and all following legislations for the
humane care of animals in research.
2.3. Methods
2.3.1. SOD formulations for therapeutic activity studies
2.3.1.1. SOD-enzymosomes. SOD-enzymosomes were prepared as
described in (Corvo et al., 2015). Brieﬂy, PC:Chol:Maleimide-PEG-
PE:PEG-PE at the molar ratio of 68.25:30.5:0.75:0.5 and dispersed in
145 mM NaCl/10 mM citrate buﬀer, pH 6.0 (20 μmol lipid/mL),
dimensioned through a ﬁnal polycarbonate membrane pore size of
0.05 μm. The conjugation was performed with a SATA:SOD molar ratio
of 4:1 and a SOD concentration of 1 mg/mL. The conjugated enzyme
was separated from the enzymosome dispersion by ultracentrifugation,
at 300,000 ×g for 120 min at 4 °C in a Beckman LM-80 ultracentrifuge.
Finally, liposomes were dispersed in 0.145 M NaCl/10 mM citrate
buﬀer pH 5.6.
2.3.1.2. SOD-liposomes. SOD-liposomes were prepared as described
before (Corvo et al., 2002). Brieﬂy, liposomes were prepared by the
dehydration-rehydration method, followed by sequential extrusion
through polycarbonate ﬁlters up to a ﬁnal pore size of 0.05 μm. The
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lipid (PC:Chol:PEG-DSPE, 1.85:1:0.15 molar ratio) concentration was
32 μmol lipid per mL hydration medium and the ﬁlm was dispersed in a
solution of SOD (5 mg/mL). Nonencapsulated enzyme was separated
from the liposome dispersion by ultracentrifugation, at 300,000 ×g for
120 min at 4 °C in a Beckman LM-80 ultracentrifuge. Finally, liposomes
were dispersed in 0.145 M NaCl/10 mM citrate buﬀer pH 5.6.
2.3.2. Characterization of the SOD-enzymosomes and SOD-liposomes
SOD content either when coupled or encapsulated to liposomes was
determined according to Lowry et al. (1951) with prior disruption of
liposomes with Triton X-100 and sodium dodecyl sulfate (Corvo et al.,
2002; Wang and Smith, 1975). Phospholipids were quantiﬁed ac-
cording to the method of Rouser et al. (1970).
The catalytic activity of SOD was measured according to Misra and
Fridovich (1972), which is based on the ability of the enzyme to inhibit
the autoxidation of epinephrine at pH 10.2. In the case of determination
of liposome-encapsulated enzyme, the enzyme was ﬁrst released from
SOD-liposomes by the addition of 20% (v/v) Triton X-100 (yielding a
dispersion containing 10% (v/v) Triton X-100). In the case of SOD-
enzymosomes, when required, vesicles were also destroyed by the ad-
dition of 20% (v/v) Triton X-100. In all activity measurements (either
the enzyme solution or the SOD-enzymosome or SOD-liposome) sus-
pensions were diluted to a concentration of 6 μg/mL [yielding a dis-
persion containing 0.3% Triton X-100 (v/v)]. The retention of enzyme
activity was deﬁned as:
=
×
Ret. Act. (Final activity Initial activity)
100 (%), taking the activity of native SOD as 100%.
The hydrodynamic diameter (z-average) and polydispersity index
(PdI) were measured in a Zetasizer Nano S from Malvern and the Zeta
potential in a Zetasizer Nano Z from Malvern.
2.3.3. Liver ischaemia-reperfusion model
Random groups of 5 animals (Wistar rats) were anaesthetized with
0.2 mL of a mixture 1:1 (v/v) of Imalgene 1000® (Merial Portuguesa
Saúde Animal Lda, Rio de Mouro, Portugal) and Domitor® (Pﬁzer
Animal Health, Pennsylvania, EUA). After anaesthetic induction, rats
were weighed, an abdominal trichotomy was performed and they were
placed on the work table. Afterwards, the abdomen was disinfected
with an aseptic solution (Cutasept®, Bode Chemie, Hamburg). A median
laparotomy was performed and the liver hilum was exposed. After the
identiﬁcation of the vascular structures, they were joined with silk 2/0
sutures. The suture was performed in the following manner: the pos-
terior perivascular fat was debrided using mosquito forceps with curved
tips and with the exposed tip of the mosquito, the silk suture was
pulled; then, a plastic cylinder object with approximately 2 cm in length
was placed and the suture knot was performed on top of this object (to
avoid vascular lesion and haemorrhage, both while suturing and while
cutting the silk). The same procedure was performed for the portal vein
and liver ischaemia was considered from this moment on.
The surgical wound was protected and there was a 30 min wait after
which the sutures were cut and liver irrigation was re-established. SOD
therapeutic treatment, SOD, SOD-liposomes, SOD-enzymosomes were
administered iv in the tail vein at a dose of 66 μg SOD per rat a few
minutes before the cut of sutures and re-establishment of liver irriga-
tion. Each treatment group contained at least 5 rats. Antisedan®
(0.2 mL) was administered to the animals for recovery from the an-
aesthesia. After 24 h, animals were sacriﬁced. Blood was collected by
cardiac puncture for the assay of liver ischaemia-reperfusion injury
biomarkers. The liver was extracted, washed with 0.154 mM KCl and
either stored at−80 °C or, when used for MRI and histological studies,
kept in a 10% (v/v) neutral buﬀered Formalin solution.
2.3.4. NF-κB translocation into the nucleus
To assess whether we were working within the inﬂammation period
of IRI the translocation into the nucleus of the transcription factor NF-
κB (p65), a well-known regulator of inﬂammatory response genes, was
assayed by Western blot. Nuclear extracts from the liver of control rats
and rats that had underwent ischaemia-reperfusion were prepared by a
modiﬁcation of the method described in (de Oliveira-Marques et al.,
2007). Brieﬂy a homogenate was made in cytosolic lysis buﬀer (10 mM
HEPES pH 7.6, 2 mM EDTA, 1.5 mM MgCl2, 10 mM KCl and 300 mM
sucrose plus freshly added 2 mM DTT, 0.1% Nonidet P-40 (v/v) and
protease inhibitors: 1 mM PMSF, 1.5 μg/mL benzamidin, 10 μg/mL
leupeptin and 1 μg/mL pepstatin). After centrifugation at 270 ×g for
30 s the supernatant was collected and centrifuged at 1500 ×g for
3 min at 4 °C. The pellet was washed once with the cytosolic lysis buﬀer
and then resuspended with the nuclear lysis buﬀer (same as the cyto-
solic buﬀer except that 420 mM NaCl, 25% (v/v) glycerol, 0.1 mM
EGTA and 0.1 mM EDTA were used, but neither sucrose nor Nonidet P-
40 were added to the buﬀer). The pellet was put on ice during 30 min
and mixed by vortexing three times during this incubation. Nuclear
proteins were collected after centrifugation at 10,000 ×g for 10 min at
4 °C. Protein concentration was assayed using the Bradford method
(Bradford, 1976).
Loading buﬀer [31.5 mM Tris-HCl pH 6.8, 10% (v/v) glycerol, 1%
(w/v) SDS, 0.005% (w/v) bromophenol blue] was added to each
sample of nuclear proteins that were then analysed by SDS-PAGE using
a 10% (w/v) polyacrylamide gel. After electrophoresis, proteins were
transferred to a nitrocellulose membrane. The primary antibody for p65
(goat polyclonal anti-p65, 1:750, sc-372 from Santa Cruz
Biotechnology, Santa Cruz, California, USA) was diluted in blocking
solution (PBS, 0.1% Tween-20, 5% milk) and incubated with the
membrane for 1 h at room temperature. The membrane was then wa-
shed three times with washing solution (PBS with 0.1% (v/v) Tween-
20) and incubated for 2 h at room temperature with peroxidase-con-
jugated anti-goat (sc-2020 from Santa Cruz Biotechnology, Santa Cruz,
California, USA). Blots were developed using an ECL chemilumines-
cence system (Millipore). After detection of the labelled bands, images
were acquired with ImageQuant LAS 500 (GE Healthcare) and protein
expression was quantiﬁed with ImageJ. The expression of p65 was
normalized using as loading control the intensity of protein bands
(stained using Ponceau-S red) in a region of the membrane similar to
the protein of interest as in (de Oliveira-Marques et al., 2007; Oliveira-
Marques et al., 2013).
2.3.5. Assessment of liver ischaemia-reperfusion injury
2.3.5.1. Haemogram and leukocyte count in blood. Blood counts of blood
samples were performed on the ADVIA® 120 Hematology System
(Siemens). The haemoglobin present in the samples was quantiﬁed at
546 nm, after lysis, using a reagent containing 20 mM potassium
cyanide and 2% (w/v) dimethyllaurylamine oxide (HGB reagent). The
leukocyte count present in the samples was obtained using three
speciﬁc reagents for the ADVIA® 120 System, including ADVIA® 120
PEROX 1 (0.36 mmol/L sodium dodecyl sulfate, 620 mmol/L sorbitol,
8.35 mmol/L NaCl, 5.5% (v/v) formaldehyde, 0.1 mmol/L Brij-35),
ADVIA® 120 PEROX 2 (44.8 mmol/L 4-chloro-1-naphthol and 99.2%
(v/v) diethylene glycol) and ADVIA® 120 PEROX 3 (0.3% (v/v) H2O2
and a stabilizer).
2.3.5.2. Enzymatic activities of liver injury biomarkers in serum. Aspartate
aminotransferase (AST), alanine aminotransferase (ALT), alkaline
phosphatase (ALP) and γ-glutamyl transferase (γ-GT) activities in
serum were used as biomarkers of ischaemia-reperfusion injury. The
enzyme activities were assayed using an ADVIA® Chemistry System
(Bayer HealthCare). AST was assayed according to Bergmeyer et al.
(1978) and 1 U is the quantity of AST that catalyzes the formation of
1 μmol of NAD+ per minute at pH 7.6 and 37 °C. ALT was determined
according to Bergmeyer and Horder (1980) and 1 U is the quantity of
ALT that catalyzes the formation of 1 μmol of NAD+ per minute at
pH 7.6 and 37 °C. γ-GT was assayed according to Shaw et al. (1977) and
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1 U is the quantity of γ-GT that catalyzes the formation 1 μmol of 5-
amino-2-nitro-benzoate per minute at pH 8.25 and 30 °C. ALP was
assayed according to Tietz et al. (1980) and 1 U is the quantity of ALP
that catalyzes the formation 1 μmol of p-nitrophenol per minute at
pH 10.3–10.4 and 30 °C.
2.3.5.3. Histological studies. For histopathological examinations, livers
were processed into paraﬃn blocks, sectioned at nominal 5 μm,
mounted on glass microscope slides and stained with haematoxylin
and eosin. The histological characterization consisted on the following
parameters: presence of inﬂammation; sinusoidal congestion; portal
congestion; centrilobular congestion; peripheral necrosis; infarctions;
ductular changes and proliferation. This characterization is in
accordance with the classiﬁcation described by Suzuki et al. (1998).
2.3.5.4. Magnetic resonance microscopy. Magnetic resonance
microscopy images were obtained at a 7 T magnetic ﬁeld in a Bruker
Avance III spectrometer equipped with a gradient magnetic ﬁeld of
160 G/cm, which allowed us the collection of Magnetic Resonance
Imaging (MRI) with high spatial resolution. The organs were immersed
in Fomblin for image acquisition.
MRM were obtained from 1 mm liver slices by a FLASH imaging
procedure with an excitation angle of 30°, a Field of View of 3 × 3 cm2,
a 256 × 256 matrix and a repetition time in a range 200 ms to 320 ms
and an echo-time of 6 to 10 ms. The signal was evaluated 8 times for
one image, and for each organ the echo-time was optimized to achieve
the best contrast.
2.4. Statistical analysis
Results are given as the mean ± standard deviation of at least 3
independent experiments made in triplicate, except where otherwise
speciﬁed. For animal experiments, data is represented as the mean ±
standard deviation and statistical signiﬁcance was tested using one-way
ANOVA test. Comparison between each pair of groups was made using
a two-tailed Student's t-test.
3. Results and discussion
3.1. Characterization of SOD-enzymosomes and SOD-liposomes
Two diﬀerent liposomal formulations, SOD-enzymosomes i.e. SOD
covalently linked to the distal end of DSPE-PEG long circulating lipo-
somes and SOD-liposomes, i.e. PEG-liposomes with encapsulated SOD
in the internal aqueous space were characterized in terms of their
particle size, loading capacities and retention of the enzymatic activ-
ities. The results of the characterizations of the two formulations are
shown in Table 1. Both formulations had the same mean size
(0.14–0.15 μm) with a low and equivalent polydispersity index. These
two parameters are crucial to enable the comparison of the in vivo
behaviour of the two formulations in terms of the long circulating
properties and the capacity of accumulation in inﬂamed areas (Corvo
et al., 1999, 2015; Martins et al., 2014). It should also to be highlighted
that both formulations had approximately the same enzyme-to-lipid
ratio (SODe/c/lipid) thus enabling targeting the same dose of enzyme
per carrier. SOD encapsulation eﬃciency for liposomes was about 2.5
fold lower than conjugation eﬃciency observed for enzymosomes
which is due to the diﬀerent technical protocols used to prepare the
nanosystems, namely the extrusion procedure for sizing liposomes
(Corvo et al., 2002). As proven earlier, the slight diﬀerence in terms of
the enzyme activity observed in both formulations does not compro-
mise the therapeutic outcomes when used in an arthritis model (Corvo
et al., 2015).
3.2. SOD-enzymosomes are more eﬀective than SOD-liposomes in
decreasing liver ischaemia-reperfusion injury
To assess IRI and whether our liposomal formulations decreased the
liver injury we used classical biochemical biomarkers of liver injury,
haematological parameters, histological analysis and MRM.
3.2.1. Enzymatic activities of liver injury biomarkers in serum
Liver IRI can be assessed by determining the activities of several
enzymes that are known biomarkers of liver cellular damage (AST, ALT,
ALP and γ-GT). AST and ALT are known as being reliable markers for
hepatocyte injury liver function leading to necrosis (Ozer et al., 2008).
Damaged hepatocytes release their contents into the extracellular
space, and so, increased levels of AST and ALT in serum indicate in-
creased permeability and damage and/or necrosis of hepatocytes (Hsieh
et al., 2015; Ozer et al., 2008). AST and ALT activities in serum have
been previously found to be increased due to ischaemia-reperfusion
injury (Gonzalez-Flecha et al., 1993). On the other hand, ALP and γ-GT,
are both enzymes associated with the hepatocyte cell membrane, and
their increased levels in the serum indicate hepatobiliary damage and
cholestasis.
In Fig. 1 we can see that after 24 h reperfusion there was a 4-fold
increase in AST activity and a 3.3-fold increase in ALT activity in rat
serum, while there were more modest increases of ALP and γ-GT ac-
tivities (a 1.3-fold for ALP and 1.5- fold for γ-GT activity). The increased
activity of all these enzymes in rat serum after indicates that IR led to
liver IRI. In contrast SHAM-operated rats showed no changes in all
enzymatic activity levels when compared to control rats (Fig. 1).
All three SOD-treatments used were eﬀective in returning ALP ac-
tivity to SHAM/Control levels, unlike the other biomarkers where there
were diﬀerences in the eﬃcacy of the SOD treatments. Treatment with
both free SOD and SOD-liposomes had no eﬀect in decreasing the
higher AST and γ-GT activities induced by IR, but decreased ALT ac-
tivity although not to SHAM levels. By contrast, upon treatment with
SOD-enzymosomes all enzymatic activities decreased more than with
the other SOD formulations with ALT, ALP and γ-GT showing no dif-
ference from activity levels found in SHAM rats. Results obtained for
AST agree with our previous studies using SOD liposomal formulations
for liver ischaemia-reperfusion (Corvo et al., 2015).
Overall, when comparing SOD-enzymosomes with SOD-liposomes
the former were more eﬀective in reducing levels of AST, ALT and γ-GT
activities after ischaemia reperfusion. So, results with biochemical liver
injury biomarkers suggest that SOD-enzymosomes are the more eﬀec-
tive formulation for decreasing IRI.
Table 1
Characteristics of SOD-enzymosomes and SOD-liposomes used for the in vivo studies.
Formulation Particle size (μm) PdI SODe/c/lipid (μg/μmol) E(/C).E. (%) Ret. Enz. act. (%)
SOD-liposomes 0.14 ± 0.02 0.070 14.4 ± 0.5 9 ± 2 > 85
SOD-enzymosomes 0.15 ± 0.02 0.178 12.5 ± 0.9 22 ± 2 60–70
SODe/c/lipid - encapsulated or conjugated SOD/lipid; E(/C).E. - encapsulated or conjugated eﬃciency; particle size – Z-average, PdI – polydispersity index.
SOD-liposomes: SOD long circulating liposomes with SOD encapsulated in the internal aqueous space of liposomes. SOD-enzymosomes: SOD covalently attached to the outer surface of
long circulating liposomes (PEG end).
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3.2.2. Inﬂammatory response and liver histological studies
Analysis of blood samples from the diﬀerent groups of animals used
in the study was performed to obtain the leukocyte count to determine
the state of the animals' immune system and, also, the amount of hae-
moglobin. Haemoglobin values (12–15 g/dL) were within the normal
range for all groups and no diﬀerences were observed between groups.
This suggests that neither the surgery nor the administration of the two
SOD liposomal formulations (SOD-Liposomes and SOD-enzymosomes)
and of “free” SOD, caused anaemia.
Inverted neutrophil-lymphocyte ratios, i.e. when the percentage of
Fig. 1. Activities of several enzymatic biomarkers
of liver ischaemia-reperfusion injury. Activities of
(A) aspartate aminotransferase (AST), (B) alanine
aminotransferase (ALT), (C) alkaline phosphatase
(ALP) and (D) γ-glutamyl transferase (γ-GT) were
determined in rat serum as described in materials
and methods. Control, rats with no ischaemia-re-
perfusion (IR) induction and no treatment; SHAM,
rats where ischaemia/reperfusion induction was
simulated; IR, rats which underwent ischaemia/
reperfusion and with no treatment. Rats that un-
derwent ischaemia-reperfusion were injected with
either free SOD (IR + SOD), SOD-liposomes (IR
+ SODLip), and with SOD-enzymosomes (IR
+ Enzymo). Values are the mean ± standard
deviation for n > (3−10) animals per group.
*P < 0.01 vs SHAM; **P < 0.05 vs SHAM;
#P < 0.01 vs IR; ǂP < 0.05 vs IR; §P < 0.05 vs
SOD; $P < 0.01 vs IR + SODLip; &P < 0.05 vs
IR + SODLip.
Fig. 2. Liver ischaemia-reperfusion does not lead to increased p65 translocation into the
nucleus. The levels of nuclear p65 were followed by western blot. (A) Representative
immunoblots of n = 4 independent experiments showing the levels of p65 in nuclear
extracts from livers of control rats (C) and of rats who had undergone ischaemia-re-
perfusion (IR) after 24 h. (B) Signal intensity quantiﬁcation of protein levels expressed as
the mean ± standard deviation in arbitrary units (a.u.) relative to control rats. Protein
levels were normalized to the protein loading using the intensity of protein bands (stained
using Ponceau-S red) in a region of the membrane similar to the protein of interest.
Table 2
Rat liver anatomical characterization after ischaemia/reperfusion. The numbers represent the number of animals in each group displaying marked liver changes from the histological
analysis.
Number of animals aﬀected
Rat treatment group Inﬂammation Sinusoidal congestion Portal congestion Centrilobular congestion Peripheral necrosis Ductular changes
Control/SHAM (n = 1) 0 0 0 0 0 0
IR (n = 5) 1 4 4 4 4 4
IR + SOD (n = 3) 0 3 3 3 3 0
IR + SODLip (n = 4) 1 1 3 3 2 0
IRI + Enzymo (n = 4) 1 2 1 2 0 1
Control, rats with no ischaemia-reperfusion induction and no treatment; SHAM, rats where ischaemia/reperfusion induction was simulated; IR, rats which underwent ischaemia/
reperfusion and with no treatment. Rats that underwent ischaemia-reperfusion were injected with either free SOD (IR + SOD), SOD-liposomes (IR + SODLip), and with SOD-en-
zymosomes (IR + Enzymo).
Fig. 3. Rat liver ischaemia reperfusion induces marginal ductular proliferation.
Representative light microphotograph of hepatic sections stained with haematoxylin and
eosin. The arrows indicate a newly formed duct.
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neutrophils is higher than the percentage of lymphocytes, may indicate
that an inﬂammation is occurring and are also associated with phy-
siological response to situations of any kind of stress or change (Simões
et al., 2005). As expected, animals of the control and sham-operated
(SHAM) groups, did not display inverted neutrophil-lymphocyte ratios.
In all the 4 operated non-treated and treated animal groups an inverted
neutrophil-lymphocyte ratio occurred in less than 30% of the animals
but there was no correlation with the treatment. We also analysed by
Western blot the nuclear levels of NF-κB (p65), a well-known tran-
scriptional regulator of inﬂammatory response genes, in control and
operated animals (Fig. 2). We found no signiﬁcant diﬀerences in the
nuclear levels of NF-κB (p65) between both groups but the high
variability in the levels of nuclear p65 from IR liver extracts, suggests
that inﬂammatory events may be happening in the liver of some of the
animals analysed. This is in agreement with the inverted neutrophil-
lymphocyte ratio found in some animals after IR. Since no signiﬁcant
changes were found in the levels of nuclear p65 after IR when compared
to control rats we did not further analyse p65 nuclear levels in the liver
of treated groups.
Rat liver from controls and SOD treated groups were analysed his-
tologically and typical parameters used to assess liver injury such as
inﬂammation, sinusoidal, portal and centrilobular congestion, periph-
eral necrosis and ductular changes were determined (see Table 2). In
animals that underwent IR, all analysed parameters were present in the
majority of animals indicating that there was IRI after 24 h. In all
groups inﬂammation was a rare event which was in accordance to re-
sults observed for p65 nuclear levels and the leucocyte proﬁle inver-
sion. The number of incidences of sinusoidal congestion, normally a
consequence of venous outﬂow impairment, decreased with all SOD
treatments but the decrease was more relevant for the animals treated
with SOD-liposomes and SOD-enzymosomes. SOD-enzymosomes were
the more eﬀective therapeutic approach to decrease portal and
centrilobular congestion or peripheral necrosis observed in the liver
after IR. These necrotic or inﬂammatory changes may be linked to the
short ischaemia period (30 min). However, the greatest distinguishing
feature of liver IRI found in the histological studies consisted of duct-
ular cell proliferation (see Fig. 3). Ductular cell proliferation in the liver
after IR was prevented with all three SOD treatments used. These
ductular changes did not occur in larger biliary pathways and are
commonly related to degenerative modiﬁcations in small biliary cana-
liculi, which are small structures consisting of 5 to 6 endothelial cells
mostly present at the periphery, that upon endothelial cell death can
obstruct the canalicular lumen. So, it can be assumed that vascular
congestion is a common and reversible histopathological occurrence in
liver after IR, but preventive antioxidant therapy, such as administra-
tion of free SOD and SOD-liposomes or SOD-enzymosomes, can prevent
injury to these small ductular structures.
Although our study was not clinically oriented, it is worth noticing
that the disappearance of peripheral small biliary structures leading to a
so-called, peripheral ductopenia, after LT or ischaemia-related biliary
disease, is a major clinical issue in LT, aﬀecting graft quality and post
LT course. Therefore, since our results showed that SOD liposomal
formulations are useful to prevent ductular damage, the use of SOD
liposomal formulations aimed at preventing a situation that can com-
promise the graft survival may deserve further investigation. Overall,
taking into account all the parameters used for rat liver anatomical
characterization to determine IRI, of the three formulations used SOD-
enzymosomes seemed to be therapeutically more eﬃcient than SOD-
liposomes, with SOD being the less eﬀective. These results are in
agreement with the biochemical studies where SOD-enzymosomes
showed a better therapeutic eﬀect than SOD-liposomes.
Fig. 4. Representative MRM obtained for slices of A) Control rat liver; B) rat liver after ischaemia-reperfusion and no treatment 24 h post-reperfusion; (IRI) C) rat liver after ischaemia-
reperfusion and treated with SOD, 24 h post reperfusion (IR + SOD); D) rat liver after ischaemia-reperfusion and treated with SOD-liposomes 24 h post reperfusion (IR + SODLip); E) rat
liver after ischaemia-reperfusion and treated with SOD-enzymossomes (IR + Enzymo), 24 h post reperfusion.
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3.3. Liver IRI can be followed by magnetic resonance micro-images
MRM imaging at a 7 T magnetic ﬁeld was obtained from slices
images of the liver from control rats and from rats who underwent
ischaemia reperfusion without or with treatment with liposomal SOD
and SOD formulations 24 h post-reperfusion (Fig. 4). As can be seen in
Fig. 4B, a high intensity signal at the periphery, as well as vasodilata-
tion was observed in liver of rats subjected to IR when compared to
liver of control rats (Fig. 4A). This highlighted that in IRI the peripheral
tissue was more aﬀected, losing its peripheral delimitation and dis-
playing dilated vascular structure, than central parts of the liver. This is
in agreement with previous results obtained with MRM where liver
tissue after IR displayed a disrupted vascular architecture when com-
pared to normal liver, with the disrupted vascular architecture occur-
ring more at the peripheral tissue than at the central tissue (Martins
et al., 2014). By the observation of Fig. 4C, it can be concluded that
treatment with free SOD (IR + SOD) had no eﬀect in the aﬀected
peripheral tissue found after IR. However, protection against IRI oc-
curred for both liposomal treatments (IR + SODLip, IR + Enzymo), as
it could be seen that the liver displayed a diﬀerent vasculature pattern
with a better preservation of the liver peripheral structure (displaying
peripheral delimitation and no vascular vasodilatation) (Fig. 4D and E).
Moreover, the liver of animals treated with SOD-enzymosomes dis-
played a more intense and homogeneous signal (Fig. 4E), when com-
pared to the liver of IR rats (Fig. 4B).
Also, results obtained by MRM agree with the activities of enzy-
matic biomarkers of liver cellular damage (Fig. 2) and with the histo-
pathological changes (Table 2 and Fig. 3) that seem to be the hallmark
of liver IRI i.e. vascular congestion, peripheral necrosis and ductular
changes. MRM images may essentially reﬂect the vascular congestion,
also found in histopathology, but do not allow to distinguish it from
injury to small biliary peripheral structures. Overall, results from MRM
images show that both liposomal formulations were able to attenuate
IRI but that SOD-enzymosomes were more eﬀective, which is in
agreement with the results obtained both with the biochemical markers
and with the histological analysis.
4. Conclusions
Biochemical biomarkers of liver injury and liver histology showed
that IRI occurs in our model of liver ischaemia reperfusion. MRM at 7 T
was used to monitor IRI and eﬀects seen on MRM images correlated
with the results from classical biochemical biomarkers of liver injury
and liver histology. Furthermore, MRM at 7 T images allowed con-
ﬁrming that the damage to the liver tissue was mostly peripheral with
biliary ductular damage and a disrupted vascular architecture as main
consequences of IRI. Thus, we were able to show that MRM at 7 T is a
useful technique to follow IRI. Also, MRM allowed to distinguish the
therapeutic eﬀects of both liposomal formulations used. Both SOD li-
posomal formulations used could attenuate liver IRI. However, SOD-
enzymosomes, where SOD is at the liposomal surface, were more ef-
fective in reducing IRI as shown by results obtained for biochemical
markers, histology and MRM and this may be due to a short therapeutic
window in liver IRI. This work conﬁrms that the use of SOD liposomal
formulations, particularly SOD-enzymosomes, for decreasing liver IRI
in a rat liver model of ischaemia reperfusion is a useful therapeutic
approach.
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